Venus Medtech (Hangzhou), Inc. Class H (HK:2500) has released an update.
Venus Medtech (Hangzhou), Inc. has announced the appointment of Mr. Bing Zhu as its new Chief Financial Officer, effective September 9, 2024. Mr. Zhu brings over three decades of experience in business and finance management, with a recent focus on China’s biotech industry supply chain. Meanwhile, the company’s shares will continue to be suspended from trading on the Stock Exchange, as per the Resumption Guidance requirements.
For further insights into HK:2500 stock, check out TipRanks’ Stock Analysis page.
